‪Adi Turjeman‬‏

970 total citations
26 papers, 302 citations indexed

About

‪Adi Turjeman‬‏ is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Infectious Diseases. According to data from OpenAlex, ‪Adi Turjeman‬‏ has authored 26 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 6 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Infectious Diseases. Recurrent topics in ‪Adi Turjeman‬‏'s work include Urinary Tract Infections Management (6 papers), Antibiotic Use and Resistance (5 papers) and Bacterial Identification and Susceptibility Testing (5 papers) ‪Adi Turjeman‬‏ is often cited by papers focused on Urinary Tract Infections Management (6 papers), Antibiotic Use and Resistance (5 papers) and Bacterial Identification and Susceptibility Testing (5 papers) ‪Adi Turjeman‬‏ collaborates with scholars based in Israel, Spain and Switzerland ‪Adi Turjeman‬‏'s co-authors include Leonard Leibovici, Dafna Yahav, Angela Huttner, Elodie von Dach, Noa Eliakim‐Raz, Mical Paul, Tanya Babich, Begoña Martínez de Tejada, Anna Kowalczyk and Ursula Theuretzbacher and has published in prestigious journals such as JAMA, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

‪Adi Turjeman‬‏

25 papers receiving 297 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
‪Adi Turjeman‬‏ Israel 8 152 76 53 45 44 26 302
George Koratzanis Greece 10 198 1.3× 44 0.6× 29 0.5× 48 1.1× 36 0.8× 14 343
Anders Lannergård Sweden 10 221 1.5× 33 0.4× 45 0.8× 25 0.6× 47 1.1× 18 363
Dan Henry United States 14 217 1.4× 38 0.5× 39 0.7× 44 1.0× 14 0.3× 18 486
Hans C. Ablij Netherlands 9 355 2.3× 37 0.5× 134 2.5× 69 1.5× 72 1.6× 9 421
Sina Helbig Germany 9 196 1.3× 32 0.4× 72 1.4× 67 1.5× 22 0.5× 20 306
Richard M. Cadle United States 8 190 1.3× 16 0.2× 47 0.9× 37 0.8× 28 0.6× 14 294
Athena L V Hobbs United States 10 129 0.8× 65 0.9× 22 0.4× 14 0.3× 47 1.1× 31 355
Merel M. C. Lambregts Netherlands 10 151 1.0× 28 0.4× 35 0.7× 35 0.8× 98 2.2× 28 307
Seung-Kwan Lim South Korea 11 184 1.2× 87 1.1× 70 1.3× 35 0.8× 28 0.6× 18 333
Rosemary Zvonar Canada 11 116 0.8× 69 0.9× 25 0.5× 12 0.3× 44 1.0× 18 304

Countries citing papers authored by ‪Adi Turjeman‬‏

Since Specialization
Citations

This map shows the geographic impact of ‪Adi Turjeman‬‏'s research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by ‪Adi Turjeman‬‏ with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites ‪Adi Turjeman‬‏ more than expected).

Fields of papers citing papers by ‪Adi Turjeman‬‏

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by ‪Adi Turjeman‬‏. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by ‪Adi Turjeman‬‏. The network helps show where ‪Adi Turjeman‬‏ may publish in the future.

Co-authorship network of co-authors of ‪Adi Turjeman‬‏

This figure shows the co-authorship network connecting the top 25 collaborators of ‪Adi Turjeman‬‏. A scholar is included among the top collaborators of ‪Adi Turjeman‬‏ based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with ‪Adi Turjeman‬‏. ‪Adi Turjeman‬‏ is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Turjeman‬‏, ‪Adi, et al.. (2025). The impact of the COVID-19 pandemic on influenza vaccination: A multi-year interrupted time series analysis. International Journal of Infectious Diseases. 159. 108015–108015. 1 indexed citations
2.
Diker‐Cohen, Talia, et al.. (2025). Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus. Diabetes & Metabolism. 51(3). 101624–101624. 2 indexed citations
3.
Steinmetz, Tali, Shira Goldman, Dana Bielopolski, et al.. (2025). The Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Type 2 Diabetes-A Real-World Study. The Journal of Clinical Endocrinology & Metabolism. 110(11). 3057–3065. 2 indexed citations
4.
5.
Abuhasira, Ran, et al.. (2024). Comparative Analysis of First-Line Antihypertensive Treatment Classes. The American Journal of Medicine. 138(3). 449–457.e7. 1 indexed citations
6.
Dotan, Idit, et al.. (2024). Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus. Transplantation. 108(7). e121–e128. 13 indexed citations
7.
Turjeman‬‏, ‪Adi, Dania Hirsch, Eyal Robenshtok, et al.. (2023). Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas. Pituitary. 27(1). 52–60. 5 indexed citations
8.
Gorshtein, Alexander, ‪Adi Turjeman‬‏, Hadar Duskin‐Bitan, Leonard Leibovici, & Eyal Robenshtok. (2023). Graves’ Disease Following COVID-19 Vaccination: A Population-based, Matched Case-control Study. The Journal of Clinical Endocrinology & Metabolism. 109(2). e508–e512. 5 indexed citations
9.
Elbaz, Meyer, et al.. (2022). Predicting In-Hospital Antibiotic Use in the Medical Department: Derivation and Validation Study. Antibiotics. 11(6). 813–813. 1 indexed citations
10.
Daitch, Vered, ‪Adi Turjeman‬‏, Noam Tau, et al.. (2022). Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis. Trials. 23(1). 1038–1038. 48 indexed citations
11.
Levy, Yochai, ‪Adi Turjeman‬‏, Lisa Cooper, et al.. (2022). Frail Older Adults with Presymptomatic SARS-CoV-2 Infection: Clinical Course and Prognosis. Gerontology. 68(12). 1393–1401. 3 indexed citations
12.
Turjeman‬‏, ‪Adi, Elodie von Dach, José Molina, et al.. (2022). Duration of antibiotic treatment for Gram-negative bacteremia – Systematic review and individual participant data (IPD) meta-analysis. EClinicalMedicine. 55. 101750–101750. 27 indexed citations
13.
Turjeman‬‏, ‪Adi, Vered Daitch, Noam Tau, et al.. (2021). Inadequate reporting of participants eligible for randomized controlled trials – A systematic review and meta-analysis. Journal of Clinical Epidemiology. 140. 125–134. 1 indexed citations
14.
15.
Martischang, Romain, Maciek Godycki-Ćwirko, Anna Kowalczyk, et al.. (2021). Risk factors for treatment failure in women with uncomplicated lower urinary tract infection. PLoS ONE. 16(8). e0256464–e0256464. 6 indexed citations
16.
Turjeman‬‏, ‪Adi, Tanya Babich, Miquel Pujol, et al.. (2021). Risk factors for enterococcal urinary tract infections: a multinational, retrospective cohort study. European Journal of Clinical Microbiology & Infectious Diseases. 40(9). 2005–2010. 6 indexed citations
17.
Babich, Tanya, Noa Eliakim‐Raz, ‪Adi Turjeman‬‏, et al.. (2021). Risk factors for hospital readmission following complicated urinary tract infection. Scientific Reports. 11(1). 6926–6926. 7 indexed citations
18.
Huttner, Angela, Anna Kowalczyk, ‪Adi Turjeman‬‏, et al.. (2018). Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. Obstetrical & Gynecological Survey. 73(8). 456–457. 7 indexed citations
19.
Leibovici, Leonard, et al.. (2018). The temptation of large numbers. Clinical Microbiology and Infection. 24(9). 931–932.
20.
Huttner, Angela, Anna Kowalczyk, ‪Adi Turjeman‬‏, et al.. (2018). Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women. JAMA. 319(17). 1781–1781. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George Koratzanis Breakdown of academic impact, for papers by Anders Lannergård Breakdown of academic impact, for papers by Dan Henry Breakdown of academic impact, for papers by Hans C. Ablij Breakdown of academic impact, for papers by Sina Helbig Breakdown of academic impact, for papers by Richard M. Cadle Breakdown of academic impact, for papers by Athena L V Hobbs Breakdown of academic impact, for papers by Merel M. C. Lambregts Breakdown of academic impact, for papers by Seung-Kwan Lim Breakdown of academic impact, for papers by Rosemary Zvonar
Rankless by CCL
2026